Evidence map›Paper›PMID 36768913›Full record

ArticleInternational journal of molecular sciences2023

Beta-Amyloid Peptide in Tears: An Early Diagnostic Marker of Alzheimer's Disease Correlated with Choroidal Thickness.

Magda Gharbiya, Giacomo Visioli, Alessandro Trebbastoni, Giuseppe Maria Albanese, Mayra Colardo, Fabrizia D'Antonio, Marco Segatto, Alessandro Lambiase

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Neuroretinal and microvascular retinal features in dementia with Lewy body assessed by optical coherence tomography angiography.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  13. New Research on Biomarkers in Alzheimer's Continuum.Reviews on recent clinical trials · 2025
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Tear Biomarkers and Alzheimer's Disease.International journal of molecular sciences · 2023
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Magda GharbiyaDepartment of Sense Organs, Sapienza University of Rome, 155, Viale del Policlinico, 00161 Rome, Italy.ORCID 0000-0002-4991-9689
Giacomo VisioliDepartment of Sense Organs, Sapienza University of Rome, 155, Viale del Policlinico, 00161 Rome, Italy.ORCID 0000-0002-6152-433X
Alessandro TrebbastoniDepartment of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
Giuseppe Maria AlbaneseDepartment of Sense Organs, Sapienza University of Rome, 155, Viale del Policlinico, 00161 Rome, Italy.ORCID 0000-0001-7562-9274
Mayra ColardoDepartment of Biosciences and Territory, University of Molise, 86100 Campobasso, Italy.ORCID 0000-0003-3353-8918
Fabrizia D'AntonioDepartment of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
Marco SegattoDepartment of Biosciences and Territory, University of Molise, 86100 Campobasso, Italy.ORCID 0000-0003-0465-9470
Alessandro LambiaseDepartment of Sense Organs, Sapienza University of Rome, 155, Viale del Policlinico, 00161 Rome, Italy.ORCID 0000-0002-8974-991X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to evaluate the diagnostic role of Alzheimer's disease (AD) biomarkers in tears as well as their association with retinal and choroidal microstructures. In a cross-sectional study, 35 subjects (age 71.7 ± 6.9 years) were included: 11 with prodromal AD (MCI), 10 with mild-to-moderate AD, and 14 healthy controls. The diagnosis of AD and MCI was confirmed according to a complete neuropsychological evaluation and PET or MRI imaging. After tear sample collection, β-amyloid peptide Aβ1-42 concentration was analyzed using ELISA, whereas C-terminal fragments of the amyloid precursor protein (APP-CTF) and phosphorylated tau (p-tau) were assessed by Western blot. Retinal layers and choroidal thickness (CT) were acquired by spectral-domain optical coherence tomography (SD-OCT). Aβ1-42 levels in tears were able to detect both MCI and AD patients with a specificity of 93% and a sensitivity of 81% (AUC = 0.91). Tear levels of Aβ1-42 were lower, both in the MCI (

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgedAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBiomarkersCross-Sectional StudiesHumansMiddle AgedPeptide Fragmentstau ProteinsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorBiomarkersPeptide Fragmentstau ProteinsAlzheimer’s diseaseAPPbeta-amyloidbiomarkerschoroidal thicknessp-tautears

Identifiers

PMID36768913
PMCPMC9917300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.